Reminder: Expert Access: Barclays KOL call: Injectable Aesthetics market dynamics and emerging innovations (Reads to IPN, GALD, ABBV)

Research evidence excerpt

Reminder: Expert Access: Barclays KOL call: Injectable Aesthetics market dynamics and emerging innovations (Reads to IPN, GALD, ABBV)

Yihan Li, PhD - European Pharma, Biotech & Life Sciences

Event Description

We are hosting an aesthetics KOL to discuss Ipsen’s Corabotase (IPN10200,

neuromodulator) data following the Saturday presentation and Monday company event,

as well as broader trends in injectable aesthetics. The call will focus on KOL interpretation

of the data, potential positioning of Corabotase, real-world prescribing patterns across

neuromodulators, fillers and biostimulators in the US, the evolving competitive landscape,

and GLP-1s' impact on Aesthetics.

•• IPN's Corabotase data read-through: KOL view on efficacy, onset of action, duration,

safety, differentiation vs current neuromodulators, and how Corabotase could fit into

practice and what level of differentiation would matter commercially.

•• Injectable aesthetics treatment patterns: Current physician use of neuromodulators,

fillers and biostimulators, including patient selection and combination use.

•• US market dynamics: Competitive positioning, switching barriers, pricing, patient

demand and brand loyalty across leading injectable products.

•• Emerging innovation: KOL perspective on faster-acting and longer-acting toxins, next-

generation fillers, biostimulators and other evolving treatment approaches.

•• "Ozempic Face" and GLP-1 driven demand: Current dynamics of GLP-1-driven

demand of injectable aesthetics, and how it will change patient needs for fillers,

biostimulators, and combination facial rejuvenation.

Relevant Research Links

Ipsen SA / Galderma: Corabotase (IPN10200, neuromodulator) LANTIC P2 preview: Durability

& safety keys to watch at SCALE; we see limited impact for GALD (14/05/2026)